Predictors | Univariable Analyses | Multivariable Analyses | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Age at diagnosis, yrs | 1.50 | 1.27–1.78 | < 0.001 | 1.46 | 1.20–1.77 | < 0.001 |
ESRD* | 1.59 | 0.91–2.78 | 0.1 | 0.99 | 0.46–2.13 | 0.9 |
Sex, men | 1.40 | 0.91–2.13 | 0.1 | 1.30 | 0.81–2.08 | 0.2 |
S-creatinine, µmol/l | 1.12 | 1.04–1.20 | 0.001 | 1.07 | 0.96–1.19 | 0.1 |
Hemoglobin | 0.84 | 0.74–0.95 | 0.005 | 0.90 | 0.77–1.05 | 0.1 |
ENT involvement | 0.60 | 0.39–0.94 | 0.02 | 0.95 | 0.54–1.66 | 0.9 |
Anti-PR3 positivity | 0.91 | 0.58–1.42 | 0.6 | 1.14 | 0.66–1.98 | 0.6 |
Early cohort | 0.88 | 0.56–1.36 | 0.5 | 0.79 | 0.47–1.33 | 0.7 |
↵* In this Cox-regression analysis, only patients in whom ESRD occurred before the infection event were included. ANCA: antineutrophil cytoplasmic antibody; ESRD: endstage renal disease; PR3: proteinase 3.